---
title: Preclinical Oncology Services - TD2 Precision Oncology
description: TD2’s integrated suite of preclinical CRO services provides our clients with data that drives the development of new oncology therapies.
---
×
[](https://td2inc.com/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
# Preclinical
[GET STARTED](https://td2inc.com/contact-us/?hsLang=en)
## *In Vivo* and *In Vitro* Services to Advance Your Drug Discovery
TD2’s integrated suite of preclinical services provides our clients with data that drives the development of clinical strategy. From the discovery stage to NDA strategy, we offer our clients advanced solutions to move their programs forward.
Our comprehensive service offerings utilized to rapidly move your treatments to the clinic include DMPK/ADME, *in vitro* and *in vivo* pharmacology, expert study design and execution. Your *in vivo* pharmacology studies are run in our AAALAC-accredited rodent facility with the highest regard for animal welfare. All studies are conducted with a commitment to meeting the high-quality standards you expect, and each offering is customizable to meet your unique development needs. With expert drug development insight and strategy and skilled project management, TD2 is your partner for an efficient path to the clinic.
## Explore our *In Vivo* and *In Vitro* Tumor Model Systems and Bioanalytical Services
TD2 Oncology accelerates preclinical drug development with a robust suite of *in vivo* and *in vitro* tumor model systems and advanced bioanalytical services, designed to generate clinically relevant insights into drug efficacy, immune response, and tumor biology. Our diverse portfolio—including syngeneic, orthotopic, patient-derived xenograft (PDX), humanized mouse, diet-induced obesity, adoptive cell therapy, and cell line-derived xenograft (CDX) models—enables precise assessment of immuno-oncology therapies, targeted agents, and combination treatments. Integrated with flow cytometry, metabolomics and proteomics analysis, DMPK/ADME services, and non-GLP safety/tolerability assessments, our approach provides translationally relevant, data-driven support to optimize drug development strategies.
What Sets TD2 Apart in Preclinical Oncology Studies:
- **Diverse & Translational Tumor Models –** Clinically relevant immunocompetent, xenograft, and humanized models tailored for oncology drug discovery.
- **Expertise in Immuno-Oncology –** Sophisticated platforms to evaluate immune checkpoint inhibitors, cell therapies, and tumor microenvironment interactions.
- **Integrated Bioanalysis Capabilities –** Flow cytometry, proteomics, and metabolomics to uncover mechanistic insights and biomarker responses.
- **Pharmacokinetics & Safety Profiling –** DMPK/ADME and non-GLP safety/tolerability studies to optimize dosing and reduce development risks.
- **Regulatory & Translational Focus –** Comprehensive preclinical strategies that align with clinical and regulatory pathways to accelerate therapeutic success.
By combining state-of-the-art tumor models with highly specialized bioanalytical services, TD2 Oncology delivers actionable data to drive informed decision-making and streamline the path to clinical translation.
## Therapeutic Spotlight
## Additional Resources
[
Preclinical
The Antitumor and Metabolomic Difference Between Male and Female Diet Induced Obese Mice Treated With Check Point Inhibitors
](https://td2inc.com/sitc-2024-poster-1364?hsLang=en)
[
Regulatory, Clinical, Preclinical, PK/ADME, Flow
Comprehensive Oncology Ecosystem
](https://td2inc.com/welcome-to-td2s-comprehensive-oncology-ecosystem?hsLang=en)
[
Regulatory, Preclinical, Videos
Advancing Antibody-Drug Conjugate Therapies: Key Preclinical and Regulatory Strategies for Clinical Success
](https://td2inc.com/lp-webinar-advancing-antibody-drug-conjugate-therapies?hsLang=en)
[
Preclinical
Model and Bioanalytical Services Catalog
](https://td2inc.com/lp-model-and-bioanalytical-services-catalog?hsLang=en)
[
Preclinical
Validated Tumor Cell Lines
](https://td2inc.com/lp-validated-tumor-cell-lines/?hsLang=en)
[
Preclinical, Posters and Publications
Epigenetic-Based Combinatorial Therapy is Synergistic in KRAS/LKB1 Mutant Non-Small Cell Lung Cancers
](https://td2inc.com/aacr-2024-poster-6491?hsLang=en)
[
Preclinical, Posters and Publications
Integrating PDX GBM In Vivo Models with Patient History and Whole Exome Sequencing: Advancing Relevance and Precision in Preclinical Studies
](https://td2inc.com/aacr-2024-poster-6908?hsLang=en)
[
Preclinical
The Importance of Metabolic and Proteomic Analyses in Identifying Treatment Pathways for Cancer Patients
](https://td2inc.com/lp-podcast-the-importance-of-metabolic-and-proteomic-analyses-in-identifying-treatment-pathways-for-cancer-patients/?hsLang=en)
[
Preclinical
Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology
](https://blog.td2inc.com/advancing-preclinical-cancer-research-through-metabolomics?hsLang=en)
[
Preclinical, Posters and Publications
E-Book: Using the Diet Induced Obese Mouse Model for Modern Cancer Research
](https://td2inc.com/ebook-using-the-diet-induced-obese-mouse-model-for-modern-cancer-research/?hsLang=en)
[
Preclinical, Posters and Publications
A Dual-specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis
](https://td2inc.com/lp-ash-2023/?hsLang=en)
[
Preclinical, Posters and Publications
Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers
](https://td2inc.com/lp-inhibition-of-hdac3-induces-brcaness-and-potent-synergy/?hsLang=en)
[
Preclinical, Posters and Publications
Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to Induce Tumor Regressions
](https://td2inc.com/lp-selective-hdac6-inhibition-by-gb-1101-revokes-tumor-immune-privilege-and-synergizes/?hsLang=en)
[
Preclinical, Posters and Publications
SITC 2023 Poster: Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice
](https://td2inc.com/lp-sitc-2023-poster/?hsLang=en)
[
Preclinical
Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites
](https://blog.td2inc.com/orthotopic-vs.-subcutaneous?hsLang=en)
[
Preclinical
Unveiling the Potential: 5 Ways DIO Mice Enhance Immuno-Oncology Discoveries
](https://blog.td2inc.com/5-ways-dio-mice-enhance-immuno-oncology-discoveries?hsLang=en)
[
Preclinical
Genetically Engineered Humanized Mouse Models: A Critical Tool for Studying Immunotherapy Drugs
](https://blog.td2inc.com/genetically-engineered-humanized-mouse-models?hsLang=en)
[
Preclinical
Diet-Induced Obesity Tumor Models for Cancer Studies
](https://blog.td2inc.com/diet-induced-obesity-tumor-models-for-cancer-studies?hsLang=en)
[
Preclinical, Posters and Publications
Metabolomics Sample Data Analysis Report
](https://td2inc.com/metabolomics-sample-data-analysis-report/?hsLang=en)
[
Preclinical, Posters and Publications
Antitumor and metabolomic evaluation of immune checkpoint inhibition in diet-induced obese mice
](https://td2inc.com/aacr-2023/?hsLang=en)
[
Clinical, Preclinical, Posters and Publications
Leading the way in defining a new Immunotherapy Response Score (IRS) to predict checkpoint inhibitor benefit
](https://td2inc.com/lp-publication-development-and-validation-of-an-integrative-pan-solid-tumor-predictor-of-pd-1-pd-l1-blockade-benefit/?hsLang=en)
[
Preclinical, Webinars
The Dynamic Trial Design
](https://td2inc.com/hubfs/Assets/Videos/td2-webinar.mp4?hsLang=en)
[
Preclinical, Webinars
Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response
](https://td2inc.com/lp-webinar-checkpoint-inhibitors/?hsLang=en)
[
Preclinical, Posters and Publications
Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers
](https://td2inc.com/hubfs/Assets/PDF-DOCS/Abstract-2607_GB-3103-Poster-2022-Final.pdf?hsLang=en)
[
Preclinical, Posters and Publications
Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to…
](https://td2inc.com/hubfs/Assets/PDF-DOCS/Abstract-1359_GB-1101-Poster-2022-Final.pdf?hsLang=en)
[
Preclinical, White Papers
Exploring the Effects of Microbiome in Precision Oncology Therapeutic Development
](https://td2inc.com/lp-white-paper-exploring-the-effects-of-microbiome-in-precision-oncology-therapeutic-development/?hsLang=en)
[
Preclinical, White Papers
Many Drugs Don’t Move Past Phase I. Will Yours?
](https://td2inc.com/many-drugs-dont-move-past-phase-i-will-yours/?hsLang=en)
[
Preclinical, White Papers
CAR T-Cell Therapy: Revolutionizing Cancer Treatment
](https://td2inc.com/hubfs/Assets/PDF-DOCS/TD2_CAR_T_Cell_October-1.pdf?hsLang=en)
[
Preclinical, White Papers
6 Signs You Need a New CRO for Your Preclinical Research
](https://td2inc.com/6-signs-you-need-a-new-cro-for-your-preclinical-research/?hsLang=en)
## The TD2 Oncology Ecosystem
### Seamless Integration from Preclinical to Clinical Success
TD2 Oncology offers a comprehensive suite of study management services, ensuring a seamless and efficient clinical trial process from preclinical stages through regulatory approvals and beyond. Our integrated approach includes:
- **[Preclinical Services](https://td2inc.com/preclinical?hsLang=en):** Leveraging innovative technology and experienced scientists to deliver robust preclinical data which guide your clinical strategy.
- **[Regulatory Support](https://td2inc.com/regulatory-support?hsLang=en):** Guiding you through the complex regulatory landscape with expert advice and documentation support for an expedited path into the clinic.
- **[Clinical Trial Management](https://td2inc.com/clinical-study-management?hsLang=en):** Providing end-to-end management of your clinical trials, from site selection and patient recruitment to data management and analysis ensuring a streamlined clinical experience.
By partnering with TD2 Oncology, you benefit from a streamlined process that minimizes delays and optimizes resource allocation, ensuring that your trial progresses smoothly at every stage. Our commitment to quality and efficiency means you can focus on your research, while we handle the operational complexities.
## GET STARTED
## Put your preclinical studies in the hands of a team who believes in your research as much as you do.
Are you ready to start your preclinical trial? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.
[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
Office
13208 E. Shea Blvd,
Suite 100
Scottsdale, AZ 85259
Phone
(602) 358-8300
Connect with us
-
-
© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)